MGC Pharma drop-ships medicinal cannabis to Brazil


MGC Pharma (ASX: MXC) has made history, becoming the first company to legally import THC containing prescription medicinal cannabis medication to Brazil.

After six months of planning and negotiation with local authorities, MGC Pharma, in partnership with their local distributor OnixCann, has successfully paved the pathway for legal import directly to patients who hold a prescription and personal import licence under the Brazilian Compassionate Use Program.

“This is an incredible achievement as no other company has shipped high THC formulations directly to patients in Brazil before. Feedback to date from patients in Brazil has been extremely positive and we are seeing rapidly increasing demand for our Mercury Pharma products,” said MGC Pharma CEO, Roby Zomer.

The Brazilian market has a population of over 210million with a pharmaceutical market of around $24billion, and currently being the sole importer of THC containing medicinal cannabis – MGC Pharma has the unique opportunity of being first to market and establishing a foothold as a key player in the region.

Initially, they will be importing their EU-GMP product range, Mercury Pharma. This range recently became available in Australia where MGC is attempting to capture market share from established providers by providing high-quality medication at a much more affordable price than previously seen.

Marcelo Galvão, Founder of OnixCann, commented, “There are more than 30,000 patients currently using homemade oils in Brazil and those patients really need quality products that we now carry with the Mercury Pharma Line.”



Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”